1. Home
  2. INGN vs VTVT Comparison

INGN vs VTVT Comparison

Compare INGN & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.30

Market Cap

172.4M

Sector

Health Care

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$35.83

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
VTVT
Founded
2001
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.4M
148.7M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
INGN
VTVT
Price
$6.30
$35.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$11.25
$53.00
AVG Volume (30 Days)
326.0K
44.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
N/A
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$14.00
52 Week High
$9.13
$44.00

Technical Indicators

Market Signals
Indicator
INGN
VTVT
Relative Strength Index (RSI) 38.58 53.97
Support Level $5.97 $34.29
Resistance Level $6.93 $41.59
Average True Range (ATR) 0.38 2.22
MACD -0.10 0.64
Stochastic Oscillator 1.74 71.84

Price Performance

Historical Comparison
INGN
VTVT

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: